Clinical Trials Logo

Clinical Trial Summary

This study is designed to explore the hypothesis that in patients with a Locally advanced rectal cancer (LARC) treated with a Total neoadjuvant therapy (TNT) strategy based on short course radiotherapy (5x5Gy) followed by neoadjuvant consolidation chemotherapy is associated with a higher rate of pathological clinical response and sustained (>1year) complete clinical response when compared to an historical cohort treated with long course chemoradiation therapy (CRT), total mesorectal excision (TME) and adjuvant chemotherapy (ACT).

Clinical Trial Description

Non-operative management with a Watch and Wait (W&W) strategy has been advocated for selected patients with a locally advanced rectal cancer (LARC) and a complete clinical response (cCR) after neoajuvant (NA) treatment. In this context, total neoadjuvant therapy (TNT), i.e the use of radiotherapy and full dose of post-operative chemotherapy as part of NA treatment, has emerged as a strategy to enhance treatment response. Currently, TNT has reported higher rates of pCR and organ preservation when compared to current standard of care. However, the best TNT strategy is still unknown. We therefore hypothesize that in LARC patients, the use of a TNT strategy based on short course RT followed by consolidation chemotherapy is associated with a higher rate of pCR and sustained (>1year) cCR when compared to an historic cohort. The main aim of the present proposal is to assess the effects of a standardized TNT model in LARC patients as a strategy for enhanced pCR/sustained cCR. For this purpose, we propose the following experimental model: In primary Aim 1 we will study if the effects of a TNT strategy over patients with a LARC enhance the rate of pCR/sustained cCR by (1) evaluating the compliance and toxicity of a TNT strategy as a proof of concept of its applicability, (2) assessing the rate of cCR at the end of TNT and (3) assessing the rate of pCR in the surgically managed subgroup and sustained cCR (>1year) in the W&W subgroup. Additionally, in primary Aim 2, we will determine if patients with a W&W strategy have better functional outcomes and quality of life (QoL) than patients treated with TME after TNT by (1) using validated questionnaires for the evaluation of bowel, sexual and urinary function for W&W and TME patients and (2) by evaluating the QoL using a widely-used standardized questionnaire. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04864067
Study type Interventional
Source Servicio de Salud Metropolitano Sur Oriente
Contact Felipe F Quezada-Diaz, MD
Phone + 562 25762401
Email [email protected]
Status Recruiting
Phase Phase 2
Start date May 1, 2021
Completion date October 30, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Recruiting NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Suspended NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1
Active, not recruiting NCT02438839 - Curative Chemoradiation of Low Rectal Cancer
Completed NCT02626728 - A Prospective Feasibility Study for TAMIS N/A
Completed NCT02399813 - Phase 2 Study of ADXS11-001 in Subjects With Carcinoma of the Anorectal Canal Phase 2
Recruiting NCT02592304 - Preoperative Assessment of Mesorectal Lymph Nodes by Dual Energy CT. PUMK-DECT N/A
Completed NCT02236884 - The Feasibility and Safety of No-scar Transanal Total Mesorectal Excision for Rectal Cancer Phase 1/Phase 2
Completed NCT02243267 - GI SPORE Colon Biosample Protocol N/A
Recruiting NCT02280070 - RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301). Phase 2
Completed NCT01938027 - The Evaluation of the Safety and the Efficacy of Transanal Total Mesorectal Excision N/A
Completed NCT02112747 - Adherence to Colon Cancer Screening (ACCS) N/A